We compared the expression of BTK protein and markers associated with B cell activation and survival, such as CD86, HLA-DR, and BAFFR, in circulating B cells between pSS patients at diagnosis, non-SS sicca patients, and healthy controls (HCs). This evidence concerns the gene CD86 and synovial sarcoma.